Kyoto University Research Infor	
Title	Growth inhibition of imatinib-resistant CML cells with the T315I mutation and hypoxia-adaptation by AV65 - a novel Wnt/ -catenin signaling inhibitor.
Author(s)	Nagao, Rina; Ashihara, Eishi; Kimura, Shinya; Strovel, Jeffrey W; Yao, Hisayuki; Takeuchi, Miki; Tanaka, Ruriko; Hayashi, Yoshihiro; Hirai, Hideyo; Padia, Janak; Strand, Kathryn; Maekawa, Taira
Citation	Cancer letters (2011), 312(1): 91-100
Issue Date	2011-12-15
URL	http://hdl.handle.net/2433/147969
Right	© 2011 Elsevier Ireland Ltd.
Туре	Journal Article
Textversion	author

1	Growth inhibition of imatinib-resistant CML cells with the
2	T315I mutation and hypoxia-adaptation by AV65, a novel
3	Wnt/β-catenin signaling inhibitor
4	
5	Rina Nagao ^a , Eishi Ashihara ^{a,b,*} , Shinya Kimura ^c , Jeffrey W. Strovel ^d , Hisayuki Yao ^a ,
6	Miki Takeuchi ^a , Ruriko Tanaka ^a , Yoshihiro Hayashi ^a , Hideyo Hirai ^a , Janak Padia ^d ,
7	Kathryn Strand ^d , and Taira Maekawa ^a
8	
9	^a Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital,
10	Kyoto, Japan
11	^b Department of Molecular Cell Physiology, Kyoto Prefectural University of Medicine,
12	Kyoto, Japan
13	^c Division of Hematology, Respiratory Medicine and Oncology, Department of Internal
14	Medicine, Faculty of Medicine, Saga University, Saga, Japan
15	^d PGX Health, A Division of Clinical Data Inc, Germantown, MD, USA
16	
17	
18	*Correspondence to:
19	Eishi Ashihara, MD, PhD.
20	Associate Professor
21	Department of Transfusion Medicine and Cell Therapy
22	Kyoto University Hospital
23	54 Kawahara-cho, Shogoin
24	Sakyo-ku, Kyoto, 606-8507
25	Japan
26	Tel: +81-75-751-3630 / Fax: +81-75-751-4283
27	e-mail: <u>ash0325@kuhp.kyoto-u.ac.jp</u>
28	
29	(Present Address)
30	Department of Molecular Cell Physiology
31	Kyoto Prefectural University of Medicine
32	465 Hirokoji, Kamigyo-ku, Kyoto, 602-8566

1	Japan
2	Tel: +81-75-251-5311 / Fax: +81-75-251-0295
3	e-mail: <u>ash@koto.kpu-m.ac.jp</u>
4	
5	
6	

1 Abstract

We investigated the effect of a novel Wnt/β-catenin signaling inhibitor, AV65 on $\mathbf{2}$ imatinib mesylate (IM)-sensitive and -resistant human chronic myeloid leukemia 3 (CML) cells in vitro. AV65 inhibited the proliferation of various CML cell lines 4 including T315I mutation-harboring cells. AV65 reduced the expression of β -catenin in $\mathbf{5}$ CML cells, resulting in the induction of apoptosis. Moreover, AV65 inhibited the 6 $\overline{7}$ proliferation of hypoxia-adapted primitive CML cells that overexpress β -catenin. The combination of AV65 with IM had a synergistic inhibitory effect on the proliferation of 8 9 CML cells. These findings suggest that AV65 could be a novel therapeutic agent for the 10 treatment of CML. 11

12

13 Key Words: β -catenin, CML, imatinib-resistance, T315I, hypoxia-adaptation

1 1. Introduction

Chronic myeloid leukemia (CML) is a disorder of hematopoietic stem cells $\mathbf{2}$ caused by constitutive activation of the Bcr-Abl tyrosine kinase [1]. Imatinib mesylate 3 4 (IM) has dramatically improved the management of CML [2,3], but IM resistance is frequently observed, especially in patients with advanced-stage disease [4]. The 5 second-generation Abl tyrosine kinase inhibitors (TKIs) including dasatinib [5], 6 nilotinib [6], bosutinib [7], and bafetinib (INNO-406) [8], have been shown to $\overline{7}$ overcome IM-resistance in CML. These agents, however, are ineffective in CML cells 8 harboring the T315I mutation [9,10]. Another important cause of recurrence of CML is 9 10 the existence of CML stem cells that are resistant to TKIs [11,12]. 11 Granulocyte-macrophage progenitors from patients in the blast crisis phase of CML or 12with IM-resistant CML have elevated levels of nuclear β -catenin [13]. Recently, a microarray study of cells from CML patients in blast crisis revealed an activation of the 13Wnt/β-catenin pathway [14]. A recent gene profile study revealed the upregulation of 14β-catenin target genes in IM-resistant CML patients in the chronic phase [15]. Moreover, 15loss of β -catenin impairs the self-renewal of CML stem cells [16]. These observations 1617indicate that Wnt/ β -catenin signaling play a role in the maintenance of CML stem cells as well as IM-resistance. Moreover, Bcr-Abl stabilizes β -catenin through tyrosine 18

1	phosphorylation [17]. Therefore, the Wnt/ β -catenin signaling pathway could be a
2	promising therapeutic target for the treatment of CML.
3	Activation of Wnt/ β -catenin signaling is closely linked to the process of
4	carcinogenesis in solid tumors [18] as well as leukemia [19,20]. Using high-throughput
5	transcriptional screening (HTS) technology, effective inhibitors of Wnt/β -catenin
6	signaling were identified from a library of more than 100,000 chemical compounds
7	[21,22]. From this initial series, a novel Wnt/β-catenin signaling pathway inhibitor
8	named AV65 was selected and optimized. In the present report, the inhibitory effect of
9	AV65 on the proliferation of various IM-sensitive and -resistant CML cell lines is
10	demonstrated.
11	
12	2. Material and methods
13	2.1. Reagents and cell lines

The human CML cell lines K562 and, MEG01, and the HL60 acute myeloid leukemia (AML) cell line, were obtained from the American Type Culture Collection (Manassas, VA). The KU812 and BV173 CML cell lines were obtained from the Japanese Collection of Research Biosources (Osaka, Japan) and the Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ) GmbH (Braunschweig,

1	Germany), respectively. The KCL22 CML cell line was kindly provided by Dr. Tadashi
2	Nagai (Jichi Medical School, Tochigi, Japan). The MYL and MYL-R1 CML cell lines
3	were kindly provided by Dr. Hideo Tanaka (Hiroshima University, Japan). The MYL-R1
4	is a Lyn-overexpressing subline of MYL [23]. The KT-1 cell line was provided by Dr.
5	Masaki Yasukawa (Ehime University, Japan) [24]. K562-IMR cells with Bcr-Abl
6	upregulation and K562/D1-9 cells with P-glycoprotein (P-gp)-overexpression were
7	kindly provided by Dr. Yoshimasa Urasaki and Dr. Dr. Takahiro Yamauchi, respectively
8	(Fukui University, Japan). The KBM5 cell line and the KBM5/STI-R subclone
9	harboring the T315I mutation were kindly provided by Dr. Miloslav Beran (MD
10	Anderson Cancer Center, Houston, TX) [25,26]. Ba/F3 cell lines expressing
11	Bcr-Abl/wild-type (wt), G250E, Q252H, Y253F, E255K, T315I, T315A, F317L, F317V,
12	M351T, or H396P were established as previously described [8]. The parental Ba/F3 cell
13	line was maintained in 10% WEHI-conditioned medium as a source of IL-3. Two
14	hypoxia-adapted (HA-) CML cell lines were generated, and these hypoxia-adapted
15	sublines from K562 and KCL22 are denoted as K562/HA and KCL22/HA, respectively.
16	Both cell lines proliferate continuously under 1.0% O ₂ for more than 1 year without any
17	additional nutrient supplies. These cell lines are resistant to IM [27,28]. Cells were
18	maintained as suspension cultures in RPMI1640 (Gibco, Tokyo, Japan) containing 10%

heat-inactivated fetal calf serum (FSC; Invitrogen, Tokyo, Japan), 2 mM L-glutamine 1 (Gibco), and 1% penicillin-streptomycin (Gibco). $\mathbf{2}$ 3 AV65, a novel Wnt/β-catenin inhibitor, was dissolved in dimethyl sulfoxide to a stock of 1 mM and stored in aliquots at -20°C until use. The caspase inhibitor zVAD, 4 which was purchased from the Peptide Institute (Osaka, Japan), was dissoloved in $\mathbf{5}$ 6 dimethyl sulfoxide and stored at -20°C until required for use. zVAD was used at 50 µM for K562 and BV173, as previously described [29]. MG132, a proteasome inhibitor, was $\overline{7}$ purchased from Sigma-Aldrich (Tokyo, Japan). 8

9

10 2.2. Growth inhibitory effect of AV65 on CML cells

11 CML cell lines were exposed to AV65 for 72 hours and cell proliferation was 12assessed using a modified MTT assay as previously described [8]. The combined effect of combination treatment with IM and AV65 was evaluated in K562 cells. Cells were 13incubated for 72 hours with six concentrations (equivalent to 0.25, 0.5, 0.75, 1.0, 1.5, or 142.0 times the IC_{50}) of AV65 alone or in combination with IM. We calculated the 15combination indexes (CIs) as reported previously [30,31], and the fraction affected (Fa) 1617at each dilution was measured (an Fa of 0.25 equals 75% viable cells). This method provides a quantification of the synergism (CI < 1) and antagonism (CI > 1) between 18

1	two drugs at different doses. Calculations of the CI were made under the assumption
2	that the mechanisms of action of the evaluated drugs were not mutually exclusive. The
3	inhibitory effects of AV65 on primary CML cells were also investigated using a colony
4	assay. Bone marrow (BM) mononuclear cells obtained from CML patients and healthy
5	volunteers (ALLCells, Emeryville, CA) were plated in duplicate in MethoCult H4434
6	Classic (StemCell Technologies Inc, Vancouver, Canada) and cultured at 37°C in 5%
7	CO ₂ . After 14 days of culture, colonies were evaluated under an inverted microscope.

9 2.3. Western blot analysis

10	Following treatment with AV-65 compounds, more than 1 x 10^6 cells were
11	collected by centrifugation. Western blotting analysis was performed as previously
12	described [27,32]. Antibodies (Abs) against β -catenin, cyclinD1, phosphorylated Erk1/2
13	(pT202/pY204) (BD, Tokyo, Japan), Oct-1, c-Myc, Stat5 (Santa Cruz Biotechnology,
14	Santa Cruz, CA), phosphorylated β -catenin (Ser33/37/Thr41), survivin, Erk1/2, Akt,
15	c-Abl, phosphorylated Akt (Ser473), phosphorylated c-Abl (Tyr245), phosphorylated
16	Stat5 (Tyr694) (Cell Signaling Technology, Danvers, MA), Actin (Sigma-Aldrich,
17	Tokyo, Japan), and GAPDH (CHEMICON, MA, USA) were used as primary Abs.
18	Horseradish peroxidase-coupled IgG (Amersham Biosciences, Tokyo, Japan) was used

1	as a secondary Ab, and immunoreactive proteins were detected by enhanced
2	chemiluminescence (ECL) or ECL-plus kits (Amersham Biosciences).
3	
4	2.4. Flow cytometric analysis
5	Cells were fixed and stained with propidium iodide (PI). Apoptosis induced by
6	AV65 was determined using the Annexin V-FITC Apoptosis Detection Kit I (BD
7	Bioscience), according to the manufacturer's instructions. Apoptosis was also evaluated
8	using PI and TdT-mediated dUTP-biotin nick-end labeling (TUNEL) to detect
9	fragmented DNA as previously described [33]. Cells were analyzed by FACS Canto II
10	using the Diva software (BD Bioscience).
10 11	using the Diva software (BD Bioscience).
	using the Diva software (BD Bioscience). 2.5. Real-time quantitative RT-PCR
11	
11 12	2.5. Real-time quantitative RT-PCR
11 12 13	2.5. Real-time quantitative RT-PCR Total RNA from K562, BV173, and KBM5 cells was extracted using the
11 12 13 14	2.5. Real-time quantitative RT-PCRTotal RNA from K562, BV173, and KBM5 cells was extracted using theQIAamp RNA Blood Mini Kit (QIAGEN, Tokyo, Japan) and subjected to reverse
11 12 13 14 15	2.5. Real-time quantitative RT-PCR Total RNA from K562, BV173, and KBM5 cells was extracted using the QIAamp RNA Blood Mini Kit (QIAGEN, Tokyo, Japan) and subjected to reverse transcription. The mRNA levels of human p21, p27, p57, and cyclin D1 were analyzed

1	target mRNAs were normalized with that of the housekeeping gene actin. The specific
2	primers for p21 were fwd, 5'-TGGAGACTCTCAGGGTCGAAA-3', and rev,
3	5'-CGGCGTTTGGAGTGGTAGAA-3'. The specific primers for p27 were fwd,
4	5'-CCGGCTAACTCTGAGGACAC-3', and rev,
5	5'-AGAAGAATCGTCGGTTGCAG-3'. The specific primers for p57 were fwd, 5'-
6	GCGGCGATCAAGAAGCTGTC-3', and rev, 5'- CCGGTTGCTGCTACATGAAC-3'.
7	The specific primers for β -catenin were fwd, 5'-GCCGGCTATTGTAGAAGCTG-3',
8	and rev, 5'-GAGTCCCAAGGAGACCTTCC-3'. The specific primers for actin were
9	fwd, 5'-CATGTACGTTGCTATCCAGGC-3', and rev,
10	5'-CTCCTTAATGTCACGCACGAT-3'.
11	
12	2.6. Measurement of caspase activity
13	Caspase-3 activity in the presence of AV65 with or without zVAD was
14	evaluated using a fluorometric protease assay kit (MBL, Aichi, Japan) as previously
15	describe [34].
16	
17	3. Results
18	3.1. AV65 inhibited the growth of IM-sensitive human CML cell lines

1	Examination of β -catenin expression in IM-sensitive CML cell lines showed
2	that the expression levels of β -catenin increased by 20- to 45-fold in the K562, BV173,
3	KT-1, and MYL CML cell lines compared with the total BM cells from healthy
4	volunteers (Fig. 1A). Assessment of the effect of AV65 showed that the inhibitor
5	reduced β -catenin expression in K562 CML cells in a time- and dose-dependent manner
6	in nuclear and cytosolic fractions, as well as in whole cell lysates (Fig. 1B).
7	The effect of AV65 on the growth inhibition of IM-sensitive CML cells was
8	examined by exposing 7 IM-sensitive human CML cell lines to AV65 for 72 hours and
9	assessing the anti-proliferative effect of this inhibitor using modified MTT assay. AV65
10	inhibited the growth of all 7 CML cell lines with IC_{50} values ranging from 9.8 to 33.1
11	nM (Fig. 1C). To investigate the inhibitory effect of AV65 on primary CML cells, the
12	number of colony-forming units (CFUs) observed following AV65 treatment of
13	hematopoietic progenitor cells obtained from 3 healthy individual donors. CML cells
14	obtained from 2 patients with CML in chronic phase was examined by colony assay on
15	day 14. When normal progenitor cells were treated with 1, 3, 10, 30, 50, 70, 100 nM of
16	AV65, the CFUs were 93.9 \pm 5.8, 91.4 \pm 7.8, 62.1 \pm 13.4, 37.6 \pm 10.3, 12.5 \pm 9.1, 1.2 \pm
17	2.0, and 0 ± 0 % of the control, respectively. When primary CML cells were treated with
18	1, 3, 10, 30, 50, 70, and 100 nM of AV65, the CFUs were 79.9 \pm 2.7, 45.8 \pm 26.1, 22.8 \pm

1 19.4, 26.2 ± 1.5 , 11.0 ± 15.52 , 1.626 ± 2.3 , and 0 ± 0 % of the control, respectively (Fig. 2 1*d*). These percentages are the mean \pm standard error of the individuals tested. These 3 observations indicate that AV65 was approximately 5 times more effective at inhibiting 4 colony formation in cells derived from CML patients than in those from healthy 5 volunteers.

6 The effect of AV65 treatment on the expression of β -catenin and its downstream targets was investigated by Western blot analysis (Fig. 2A). AV65 downregulated the $\overline{7}$ expression of phosphorylated and total β -catenin. Moreover, the expression of c-myc 8 and survivin were also reduced by AV65 treatment. Another work form our group 9 10 demonstrated that AV65 promotes the degradation of β -catenin via the ubiquitin-proteasome pathway (Yao, in revision). Therefore, we investigated the 11 12inhibitory effect of the proteasome inhibitor MG132 on the degradation of β -catenin by AV65. MG132 expectedly inhibited the degradation of β-catenin (Supplementary Fig. 13S3). 14

15

16 *3.2. AV65 caused cell arrest at the G1 phase to S phase transition and induced* 17 *apoptosis in CML cells*

18 To investigate the cell cycle phases involved in cell death induced by AV65in

1	CML cells, co-staining of cells by PI and TUNEL was performed to detect DNA
2	fragmentation. Double staining revealed that both K562 and BV173 arrested at the G1
3	to S phase transition in response to AV65 treatment at 30 nM for 12 hours (Fig. 3A).
4	Cell cycle analysis also showed that AV65 treatment increased the G1 phase population
5	in these 2 cell lines in a time- and dose-dependent manner, coincident with an increase
6	in the number of cells in subG1 phase (Fig. 3B). To further identify the mechanism of
7	cell cycle-dependent cell death, the transcript levels of cyclin-dependent kinase
8	inhibitors (CKIs) were assessed during the G1 phase in CML cell lines. Real time PCR
9	analysis showed that the transcripts of p21, p27, and p57 were increased by AV65
10	treatment in K562, BV173, and KBM5 cells. However, p53 transcript levels in these
11	cell lines were not altered by AV65 treatment (Fig. 3C). These data indicate that AV65
12	induced cell cycle arrest in a p53-independent manner.
13	Assessment of apoptosis by PI/Annexin V double staining revealed that AV65
14	induced apoptosis in K562 and BV173 cell lines in a time- and dose-dependent manner
15	(Fig. 4A). Treatment with zVAD partially suppressed AV65-induced apoptosis in

- 16 BV173 cells, which indicates that AV65 induced caspase-dependent apoptosis in BV173
- 17 cells (Fig. 4B). In K562 cells, however, the effect of AV65 on the induction of apoptosis
- 18 did not change with zVAD treatment (Fig. 4B), despite the inhibition of caspase-3 by

1	zVAD (data not shown). These results show that AV65 inhibited β -catenin/T cell factor
2	(TCF) transcription signaling, which result in cell cycle arrest in the G1 phase through
3	the upregulation of CKIs and the induction of apoptosis in CML cells.

5 *3.3. AV65 enhanced the effect of imatinib*

Bcr-Abl is reported to stabilize β -catenin in CML cells through tyrosine 6 $\overline{7}$ phosphorylation [17]. The expression pattern of Bcr-Abl and its downstream effector proteins was therefore examined (Supplementary Fig. S1). Interestingly, the expression 8 of Bcr-Abl and its phosphorylated form was downregulated by AV65, and the levels of 9 phosphorylated Erk1/2, Akt, and Stat5 were also decreased. To investigate the combined 10 11 effects of AV65 and IM on K562 cells, cell proliferation was assessed using a modified 12MTT assay with 6 concentrations $(0.25, 0.5, 0.75, 1.0, 1.5, \text{ or } 2.0 \text{ times the IC}_{50})$ of each agent or a combination using a constant ratio of one of the drugs. The IC₅₀ value for 13AV65, which was obtained as described above, was 10 nM, and that of IM was 100 µM. 14The CIs and the Fa values at each dilution were calculated using the CalcuSyn software. 15Dose-effects and CI-Fa plots describing the effects of AV65 and IM combinations are 1617shown in Fig. 5. As shown in Fig. 5A, combination treatment with AV65 and IM caused a greater inhibition of cell growth each agent alone. Data derived from the analysis of 18

1	CI-Fa plots are shown in Fig. 5B. The CIs at Fa 0.5 and Fa 0.8 were 1.07 and 0.88,
2	respectively, indicating that AV65 and IM had an additive effect at lower concentrations
3	and a synergistic effect at higher concentrations.
4	
5	3.4. AV65 inhibited the growth of IM-resistant CML cells
6	The effect of AV65 was investigated 4 IM-resistant CML cells, namely,
7	KBM5/STI-R (harboring the T315I mutatuion), K562/IMR (containing a Bcr-Abl
8	amplification), MYL-R1 (Lyn overexpressing), and K562/D1-9 (P-gp overexpressing).
9	The IC50 values for AV65 in KBM5/STI-R, K562/IMR, MYL-R1, and K562/D1-9 cells
10	were 16.0, 10.0, 47.7, and 60.1 nM, respectively, and the response of these IM-resistant
11	cell lines were similar to those of their parental cell lines with the exception of
12	K562/D1-9 (Fig. 6A). AV65 induced apoptosis in KBM5/STI-R and KBM5 cells (Fig.
13	6B). Evaluation of effects of AV65 on Ba/F3 cells expressing 10 different Bcr-Abl
14	mutations showed that AV65 inhibited the growth of Ba/F3 cells harboring various
15	mutations, including T315I with IC_{50} values ranging from 21.6 to 46.5 nM
16	(Supplementary Fig. S2).
17	

3.5. AV65 is also effective in primitive HA-CML cells 18

1	The effect of AV65 was examined in the HA-CML cell lines, K562/HA and
2	KCL22/HA. These cells have a phenotype that mimics characteristics of primitive
3	leukemia cells [27,28]. In Western blotting analysis, K562/HA and KCL22/HA cells
4	expressed higher levels of β -catenin than their respective parental cells. AV65 inhibited
5	the growth of K562/HA and KCL22/HA cells at a concentration similar to that effective
6	in the inhibition of growth in the parental cell lines (Fig. 6C). These observations
7	indicate that AV65 could be effective in the inhibition of the growth of primitive CML
8	cells that overexpress β -catenin.

10 4. **Discussion**

11 Recently, activation of the Wnt/ β -catenin signaling pathway has been 12 implicated in the progression of CML. The granulocyte-macrophage progenitors from 13 patients with CML in the blast crisis phase and IM-resistant CML have elevated levels 14 of nuclear β -catenin, resulting in the transcriptional activation of TCF proteins [13]. 15 Gene expression profile studies demonstrated that Wnt/ β -catenin signaling is activated 16 in IM-resistant and advanced-stage CML [14,15], and this effect could be caused by 17 glycogen synthase kinase 3 β missplicing [35].

18

 β -catenin is a downstream effector of the canonical Wnt signaling pathway.

1	The activation of the Wnt pathway is closely linked to carcinogenesis [18,36]. While the
2	N-terminal phosphorylation of β -catenin triggers its ubiquitination and degradation by
3	the 26S proteasome [37], the stabilized form of β -catenin translocates into the nucleus
4	and activates the transcription of Wnt target genes including c-myc, survivin, and cyclin
5	D1, resulting in the proliferation of cancer cells. β -catenin therefore is considered a
6	therapeutic target for the development of anticancer drugs[32,38-40], In prior studies,
7	AV65 was identified as a novel inhibitor of Wnt/β -catenin signaling using
8	transcriptional profiling and HTS technology [21,22], Gene expression profiles before
9	and after siNRA-mediated knockdown of β -catenin were compared, and candidate
10	genes that were modulated by the inhibition of the pathway were identified. A
11	consensus set of candidate genes was identified and their transcriptional profiles were
12	validated using a series of small molecule probes capable of inhibiting the
13	Wnt/ β -catenin pathway. An early stage series of compounds was selected for further
14	analysis as inhibitors of the Wnt/ β -catenin pathway. Ultimately, AV-65 was generated
15	(Yao, in revision).
16	In the present study, the effect of AV65 on the suppression of the proliferation

17 of IM-sensitive and -resistant CML cells was demonstrated. AV65 decreased β -catenin 18 protein levels in CML cell lines in a time- and dose-dependent manner (Fig. 1B). Work

1	from our group reveled that AV65 promotes the degradation of β -catenin via the
2	ubiquitin-proteasome pathway (Yao, in revision). β -catenin translocation to the nucleus
3	decreased in response to AV65 treatment (Fig. 1B). As we have demonstrated that AV65
4	decreased TCF transcriptional activity (Yao, in revision), the expression of its
5	downstream proteins including c-myc and survivin were also reduced (Fig. 2A),
6	resulting in cell growth inhibition. As expected, the proteasome inhibitor suppressed the
7	degradation of β -catenin by AV65 (Supplementary Fig. S3). Flow cytometric analysis
8	showed that AV65 induced caspase-dependent apoptosis in BV173 cells, but apoptosis
9	was caspase-independent in K562 cells. These results suggest that the effect of AV65 on
10	induction of apoptosis in CML cells may or may not be accompanied by the activation
11	of caspases and that apoptosis with caspase activation varies depending on the CML cell
12	type, as previously observed [29]. The present results, together with other data from our
13	group (Yao, in revision), showed that AV65 inhibited TCF transcriptional activity by
14	promoting the degradation of β -catenin, which resulted in the induction of cell death.
15	The inhibition of TCF transcriptional activity by AV65 caused the downregulation of the
16	expression of survivin and c-myc, which are downstream effectors of β -catenin.
17	Interestingly, AV65 also decreased the expression of the phosphoryalted forms of
18	Bcr-Abl, Erk1/2, Akt, and Stat5 (Supplementary Fig. S1). Although this mechanism

remains still unclear, these observations suggest that Wnt/β-catenin signaling might play
 a role in the stabilization of Bcr-Abl. Further investigations are necessary to clarify this
 issue.

Frizzled2 and Lymphoid enhancer-binding factor-1 as well as β-catenin are
upregulated in CD34-positive CML cells during the disease progression from chronic
phase to blastic crisis, and Wnt3a increases β-catenin expression in CD34-positive CML
cells [41]. These observations suggest that Wnt/β-catenin signaling plays an important
role in the CML progression. Therefore, the strategy targeting Wnt/β-catenin signaling
might be also effective for the treatment of advanced-stage CML.

In the present study, the effects of AV65 were shown to be independent from 10 11 Bcr-Abl expression levels, Lyn overexpression, or the Abl T315I mutation in human 12CML cell lines. AV65 is also effective against Ba/F3 cells expressing different mutant forms of Bcr-Abl, including T315I. These observations indicate that AV65 is effective 13against IM-resistant CML cells. Importantly, AV65 inhibited the growth of CML cells 14harboring the T315I mutation. To overcome IM-resistance in CML, a second generation 15of TKIs has been developed. However, the T315I mutation confers resistance to all 1617known TKIs [9,42]. Moreover, studies have demonstrated that patients with the T315I mutation have a poor prognosis [43,44]. The development of novel agents directed 18

1	against the T315I clone is therefore important, and several multi-targeted kinase
2	inhibitors have recently been shown to be effective against the T315I mutation [45-47].
3	The present data demonstrate the potential of the AV65 compound as a novel agent
4	against CML with the T315I mutation. However, the IC_{50} value of AV65 in K562/D1-9
5	cells (P-gp overexpressing) was approximately 60.1 nM, which was higher than the IC_{50}
6	in the parental cell line and in other IM-resistant cells. This observation suggests that
7	AV65 is a substrate of P-gp. As IM is currently the drug of choice for the treatment of
8	CML, the effects of combination treatment with AV65 and IM were investigated and the
9	results showed that AV65 enhanced the inhibitory effects of IM (Fig. 5).
10	AV65 also inhibited the growth of hypoxia-adapted CML cell lines at
10 11	AV65 also inhibited the growth of hypoxia-adapted CML cell lines at concentrations comparable with those shown to be effective in the respective parental
11	concentrations comparable with those shown to be effective in the respective parental
11 12	concentrations comparable with those shown to be effective in the respective parental cell lines. Although a definite CML stem cell niche has not been identified, leukemic
11 12 13	concentrations comparable with those shown to be effective in the respective parental cell lines. Although a definite CML stem cell niche has not been identified, leukemic stem cells are located in an osteoblastic niche [48,49], which is a hypoxic region of the
11 12 13 14	concentrations comparable with those shown to be effective in the respective parental cell lines. Although a definite CML stem cell niche has not been identified, leukemic stem cells are located in an osteoblastic niche [48,49], which is a hypoxic region of the BM [27], The self-renewal of normal hematopoietic stem cells favors hypoxia [50] and
 11 12 13 14 15 	concentrations comparable with those shown to be effective in the respective parental cell lines. Although a definite CML stem cell niche has not been identified, leukemic stem cells are located in an osteoblastic niche [48,49], which is a hypoxic region of the BM [27], The self-renewal of normal hematopoietic stem cells favors hypoxia [50] and resistance to hypoxia is one of the defining features of leukemic stem cells [51]. HA

1	characteristics [27]. Interestingly, these HA cells showed a higher level of β -catenin
2	expression (Fig. 6C). This observation is consistent with the results reported by Dr.
3	Jamieson [13]. Assuming that HA-CML cells exhibit characteristics similar to those of
4	CML stem cells, the effects of AV65 on CML-HA cells were examined. AV65 inhibited
5	the growth of HA-CML cells at similar concentrations to those inhibiting the growth of
6	parental cells. In conclusion, AV65 inhibited the growth of CML cells harboring the
7	T315I mutation and primitive CML cells. The present findings indicate that β -catenin
8	could be a therapeutic target in CML, and suggest that AV65 is a potential novel
9	therapeutic agent for the treatment of CML.
10	
11	Conflicts of interest
12	R. Nagao, E. Ashihara, S. Kimura, H. Yao, M. Takeuchi, R. Tanaka, Y.
13	Hayashi, H. Hirai, and Taira Maekawa disclose no financial conflict of interest. J.W.
14	Strovel, Janak Padia, and Kathyrn Strand are employees of PGx Health, A Division of
15	Clinical Data, Inc.
16	
17	Acknowledgements
18	The authors are grateful to Ms. Yoko Nakagawa for her excellent technical

1	support. This work was supported in part by Grant-in-Aids for Scientific Research
2	and the Global COE Program "Center for Frontier Medicine" from the Ministry of
3	Education, Culture, Sports, Science and Technology (MEXT) of Japan, and by Grants
4	from the Yasuda Medical Foundation and the Fujiwara Memorial
5	Foundation.

1 References

3	[1]C.L. Sawyers, Chronic myeloid leukemia. N. Engl. J. Med. 340 (1999) 1330-1340.
4	[2]J.M. Goldman, J.V. Melo, Chronic myeloid leukemiaadvances in biology and new
5	approaches to treatment. N. Engl. J. Med. 349 (2003) 1451-1464.
6	[3]B.J. Druker, F. Guilhot, S.G. O'Brien, I. Gathmann, H. Kantarjian, N. Gattermann,
7	M.W. Deininger, R.T. Silver, J.M. Goldman, R.M. Stone, F. Cervantes, A. Hochhaus,
8	B.L. Powell, J.L. Gabrilove, P. Rousselot, J. Reiffers, J.J. Cornelissen, T. Hughes, H.
9	Agis, T. Fischer, G. Verhoef, J. Shepherd, G. Saglio, A. Gratwohl, J.L. Nielsen, J.P.
10	Radich, B. Simonsson, K. Taylor, M. Baccarani, C. So, L. Letvak, R.A. Larson,
11	Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N.
12	Engl. J. Med. 355 (2006) 2408-2417.
13	[4]A. Hochhaus, P. La Rosee, Imatinib therapy in chronic myelogenous leukemia:
14	strategies to avoid and overcome resistance. Leukemia 18 (2004) 1321-1331.
15	[5]H. Kantarjian, N.P. Shah, A. Hochhaus, J. Cortes, S. Shah, M. Ayala, B. Moiraghi, Z.
16	Shen, J. Mayer, R. Pasquini, H. Nakamae, F. Huguet, C. Boque, C. Chuah, E.
17	Bleickardt, M.B. Bradley-Garelik, C. Zhu, T. Szatrowski, D. Shapiro, M. Baccarani,
18	Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid

1	leukemia. N. Engl. J. Med. 362 (2010) 2260-2270.
2	[6]G. Saglio, D.W. Kim, S. Issaragrisil, P. le Coutre, G. Etienne, C. Lobo, R. Pasquini,
3	R.E. Clark, A. Hochhaus, T.P. Hughes, N. Gallagher, A. Hoenekopp, M. Dong, A.
4	Haque, R.A. Larson, H.M. Kantarjian, Nilotinib versus imatinib for newly diagnosed
5	chronic myeloid leukemia. N. Engl. J. Med. 362 (2010) 2251-2259.
6	[7]M. Puttini, A.M. Coluccia, F. Boschelli, L. Cleris, E. Marchesi, A. Donella-Deana, S.
7	Ahmed, S. Redaelli, R. Piazza, V. Magistroni, F. Andreoni, L. Scapozza, F. Formelli,
8	C. Gambacorti-Passerini, In vitro and in vivo activity of SKI-606, a novel Src-Abl
9	inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res. 66 (2006)
10	11314-11322.
11	[8]S. Kimura, H. Naito, H. Segawa, J. Kuroda, T. Yuasa, K. Sato, A. Yokota, Y.
12	Kamitsuji, E. Kawata, E. Ashihara, Y. Nakaya, H. Naruoka, T. Wakayama, K. Nasu,
13	T. Asaki, T. Niwa, K. Hirabayashi, T. Maekawa, NS-187, a potent and selective dual
14	Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant
15	leukemia. Blood 106 (2005) 3948-3954.
16	[9]Y. Deguchi, S. Kimura, E. Ashihara, T. Niwa, K. Hodohara, Y. Fujiyama, T.
17	Maekawa, Comparison of imatinib, dasatinib, nilotinib and INNO-406 in

1	[10]R. Tanaka, S. Kimura, Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I:
2	from the second to third generation. Expert. Rev. Anticancer Ther. 8 (2008)
3	1387-1398.
4	[11]F. Michor, T.P. Hughes, Y. Iwasa, S. Branford, N.P. Shah, C.L. Sawyers, M.A.
5	Nowak, Dynamics of chronic myeloid leukaemia. Nature 435 (2005) 1267-1270.
6	[12]M. Copland, A. Hamilton, L.J. Elrick, J.W. Baird, E.K. Allan, N. Jordanides, M.
7	Barow, J.C. Mountford, T.L. Holyoake, Dasatinib (BMS-354825) targets an earlier
8	progenitor population than imatinib in primary CML but does not eliminate the
9	quiescent fraction. Blood 107 (2006) 4532-4539.
10	[13]C.H. Jamieson, L.E. Ailles, S.J. Dylla, M. Muijtjens, C. Jones, J.L. Zehnder, J.
11	Gotlib, K. Li, M.G. Manz, A. Keating, C.L. Sawyers, I.L. Weissman,
12	Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis
13	CML. N. Engl. J. Med. 351 (2004) 657-667.
14	[14]J.P. Radich, H. Dai, M. Mao, V. Oehler, J. Schelter, B. Druker, C. Sawyers, N. Shah,
15	W. Stock, C.L. Willman, S. Friend, P.S. Linsley, Gene expression changes associated
16	with progression and response in chronic myeloid leukemia. Proc. Natl. Acad. Sci. U.
17	S. A. 103 (2006) 2794-2799.
18	[15]S.K. McWeeney, L.C. Pemberton, M.M. Loriaux, K. Vartanian, S.G. Willis, G.

1	Yochum, B. Wilmot, Y. Turpaz, R. Pillai, B.J. Druker, J.L. Snead, M. MacPartlin, S.G.
2	O'Brien, J.V. Melo, T. Lange, C.A. Harrington, M.W. Deininger, A gene expression
3	signature of CD34+ cells to predict major cytogenetic response in chronic-phase
4	chronic myeloid leukemia patients treated with imatinib. Blood 115 (2010) 315-325.
5	[16]C. Zhao, J. Blum, A. Chen, H.Y. Kwon, S.H. Jung, J.M. Cook, A. Lagoo, T. Reya,
6	Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo.
7	Cancer Cell 12 (2007) 528-541.
8	[17]A.M. Coluccia, A. Vacca, M. Dunach, L. Mologni, S. Redaelli, V.H. Bustos, D.
9	Benati, L.A. Pinna, C. Gambacorti-Passerini, Bcr-Abl stabilizes beta-catenin in
10	chronic myeloid leukemia through its tyrosine phosphorylation. Embo. J. 26 (2007)
11	1456-1466.
12	[18]M. Katoh, M. Katoh, WNT signaling pathway and stem cell signaling network. Clin
13	Cancer Res. 13 (2007) 4042-4045.
14	[19]L. Ysebaert, G. Chicanne, C. Demur, F. De Toni, N. Prade-Houdellier, J.B.
15	Ruidavets, V. Mansat-De Mas, F. Rigal-Huguet, G. Laurent, B. Payrastre, S. Manenti,
16	C. Racaud-Sultan, Expression of beta-catenin by acute myeloid leukemia cells
17	predicts enhanced clonogenic capacities and poor prognosis. Leukemia 20 (2006)
18	1211-1216.

1	[20]Q.L. Wu, C. Zierold, E.A. Ranheim, Dysregulation of Frizzled 6 is a critical
2	component of B-cell leukemogenesis in a mouse model of chronic lymphocytic
3	leukemia. Blood 113 (2009) 3031-3039.
4	[21]K.J. Strand, H. Khalak, J.W. Strovel, R. Ebner, M. Augustus, Expression biomarkers
5	for clinical efficacy and outcome prediction in cancer. Pharmacogenomics 7 (2006)
6	105-115.
7	[22]D. Bol, R. Ebner, Gene expression profiling in the discovery, optimization and
8	development of novel drugs: one universal screening platform. Pharmacogenomics 7
9	(2006) 227-235.
10	[23]T. Ito, H. Tanaka, A. Kimura, Establishment and characterization of a novel
11	imatinib-sensitive chronic myeloid leukemia cell line MYL, and an imatinib-resistant
12	subline MYL-R showing overexpression of Lyn. Eur. J. Haematol. 78 (2007)
13	417-431.
14	[24]K. Yanagisawa, H. Yamauchi, M. Kaneko, H. Kohno, H. Hasegawa, S. Fujita,
15	Suppression of cell proliferation and the expression of a bcr-abl fusion gene and
16	apoptotic cell death in a new human chronic myelogenous leukemia cell line, KT-1,
17	by interferon-alpha. Blood 91 (1998) 641-648.
18	[25]M. Beran, P. Pisa, S. O'Brien, R. Kurzrock, M. Siciliano, A. Cork, B.S. Andersson,

1	V. Kohli, H. Kantarjian, Biological properties and growth in SCID mice of a new
2	myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous
3	leukemia cells in the blastic phase. Cancer Res. 53 (1993) 3603-3610.
4	[26]H. Zhang, D. Trachootham, W. Lu, J. Carew, F.J. Giles, M.J. Keating, R.B.
5	Arlinghaus, P. Huang, Effective killing of Gleevec-resistant CML cells with T315I
6	mutation by a natural compound PEITC through redox-mediated mechanism.
7	Leukemia 22 (2008) 1191-1199.
8	[27]M. Takeuchi, S. Kimura, J. Kuroda, E. Ashihara, M. Kawatani, H. Osada, K.
9	Umezawa, E. Yasui, M. Imoto, T. Tsuruo, A. Yokota, R. Tanaka, R. Nagao, T.
10	Nakahata, Y. Fujiyama, T. Maekawa, Glyoxalase-I is a novel target against Bcr-Abl+
11	leukemic cells acquiring stem-like characteristics in a hypoxic environment. Cell
12	Death. Differ. 17 (2010) 1211-1220.
13	[28]M. Takeuchi, E. Ashihara, Y. Yamazaki, S. Kimura, Y. Nakagawa, R. Tanaka, H.
14	Yao, R. Nagao, Y. Hayashi, H. Hirai, T. Maekawa, Rakicidin A effectively induces
15	apoptosis in hypoxia adapted Bcr-Abl positive leukemic cells. Cancer Sci. 102
16	(2011) 591-596.
17	[29]Y. Kamitsuji, J. Kuroda, S. Kimura, S. Toyokuni, K. Watanabe, E. Ashihara, H.

18 Tanaka, Y. Yui, M. Watanabe, H. Matsubara, Y. Mizushima, Y. Hiraumi, E. Kawata, T.

1	Yoshikawa, T. Maekawa, T. Nakahata, S. Adachi, The Bcr-Abl kinase inhibitor						
2	INNO-406 induces autophagy and different modes of cell death execution in						
3	Bcr-Abl-positive leukemias. Cell Death. Differ. 15 (2008) 1712-1722.						
4	[30]E. Kawata, E. Ashihara, Y. Nakagawa, T. Kiuchi, M. Ogura, H. Yao, K. Sakai, R.						
5	Tanaka, R. Nagao, A. Yokota, M. Takeuchi, S. Kimura, H. Hirai, T. Maekawa,						
6	combination of a DNA-chimera siRNA against PLK-1 and zoledronic acid						
7	suppresses the growth of malignant mesothelioma cells in vitro. Cancer Lett. 294						
8	(2010) 245-253.						
9	[31]S. Kimura, J. Kuroda, H. Segawa, K. Sato, M. Nogawa, T. Yuasa, O.G. Ottmann, T.						
10	Maekawa, Antiproliferative efficacy of the third-generation bisphosphonate,						
11	zoledronic acid, combined with other anticancer drugs in leukemic cell lines. Int. J.						
12	Hematol. 79 (2004) 37-43.						
13	[32]E. Ashihara, E. Kawata, Y. Nakagawa, C. Shimazaski, J. Kuroda, K. Taniguchi, H.						
14	Uchiyama, R. Tanaka, A. Yokota, M. Takeuchi, Y. Kamitsuji, T. Inaba, M. Taniwaki,						
15	S. Kimura, T. Maekawa, beta-catenin small interfering RNA successfully suppressed						
16	progression of multiple myeloma in a mouse model. Clin. Cancer Res. 15 (2009)						
17	2731-2738.						

18 [33]S. Kimura, T. Maekawa, K. Hirakawa, A. Murakami, T. Abe, Alterations of c-myc

1	expression by antisense oligodeoxynucleotides enhance the induction of apoptosis in
2	HL-60 cells. Cancer Res. 55 (1995) 1379-1384.
3	[34]I. Kubonishi, I. Miyoshi, Establishment of a Ph1 chromosome-positive cell line
4	from chronic myelogenous leukemia in blast crisis. Int. J. Cell Cloning 1 (1983)
5	105-117.
6	[35]A.E. Abrahamsson, I. Geron, J. Gotlib, K.H. Dao, C.F. Barroga, I.G. Newton, F.J.
7	Giles, J. Durocher, R.S. Creusot, M. Karimi, C. Jones, J.L. Zehnder, A. Keating, R.S.
8	Negrin, I.L. Weissman, C.H. Jamieson, Glycogen synthase kinase 3beta missplicing
9	contributes to leukemia stem cell generation. Proc. Natl. Acad. Sci. U. S. A. 106
10	(2009) 3925-3929.
11	[36]P. Polakis, The many ways of Wnt in cancer. Curr. Opin. Genet. Dev. 17 (2007)
12	45-51.
13	[37]H. Aberle, A. Bauer, J. Stappert, A. Kispert, R. Kemler, beta-catenin is a target for
14	the ubiquitin-proteasome pathway. Embo. J. 16 (1997) 3797-3804.
15	[38]S. Dihlmann, M. von Knebel Doeberitz, Wnt/beta-catenin-pathway as a molecular
16	target for future anti-cancer therapeutics. Int. J. Cancer 113 (2005) 515-524.
17	[39]M. Lepourcelet, Y.N. Chen, D.S. France, H. Wang, P. Crews, F. Petersen, C. Bruseo,
18	A.W. Wood, R.A. Shivdasani, Small-molecule antagonists of the oncogenic

1	Tcf/beta-catenin protein complex. Cancer Cell 5 (2004) 91-102.
2	[40]H. Yao, E. Ashihara, T. Maekawa, Targeting the Wnt/beta-catenin signaling pathway
3	in human cancers. Expert Opin. Ther. Targets 15 (2011) 87
4	[41]A. Sengupta, D. Banerjee, S. Chandra, S.K. Banerji, R. Ghosh, R. Roy, S. Banerjee,
5	Deregulation and cross talk among Sonic hedgehog, Wnt, Hox and Notch signaling
6	in chronic myeloid leukemia progression. Leukemia 21 (2007) 949-955.
7	[42]H.A. Bradeen, C.A. Eide, T. O'Hare, K.J. Johnson, S.G. Willis, F.Y. Lee, B.J. Druker,
8	M.W. Deininger, Comparison of imatinib mesylate, dasatinib (BMS-354825), and
9	nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen:
10	high efficacy of drug combinations. Blood 108 (2006) 2332-2338.
11	[43]S. Soverini, S. Colarossi, A. Gnani, G. Rosti, F. Castagnetti, A. Poerio, I. Iacobucci,
12	M. Amabile, E. Abruzzese, E. Orlandi, F. Radaelli, F. Ciccone, M. Tiribelli, R. di
13	Lorenzo, C. Caracciolo, B. Izzo, F. Pane, G. Saglio, M. Baccarani, G. Martinelli,
14	Contribution of ABL kinase domain mutations to imatinib resistance in different
15	subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic
16	Myeloid Leukemia. Clin. Cancer Res. 12 (2006) 7374-7379.
17	[44]F.E. Nicolini, S. Hayette, S. Corm, E. Bachy, D. Bories, M. Tulliez, F. Guilhot, L.
18	Legros, F. Maloisel, J.J. Kiladjian, F.X. Mahon, Q.H. Le, M. Michallet, C.

1	Roche-Lestienne, C. Preudhomme, Clinical outcome of 27 imatinib							
2	mesylate-resistant chronic myelogenous leukemia patients harboring a T315I							
3	BCR-ABL mutation. Haematologica 92 (2007) 1238-1241.							
4	[45]R. Tanaka, M.S. Squires, S. Kimura, A. Yokota, R. Nagao, T. Yamauchi, M							
5	Takeuchi, H. Yao, M. Reule, T. Smyth, J.F. Lyons, N.T. Thompson, E. Ashihara, O.G.							
6	Ottmann, T. Maekawa, Activity of the multi-targeted kinase inhibitor, AT9283, in							
7	imatinib-resistant BCR-ABL positive leukemic cells. Blood 116 (2010) 2089-2095.							
8	[46]Y. Shiotsu, H. Kiyoi, Y. Ishikawa, R. Tanizaki, M. Shimizu, H. Umehara, K. Ishii, Y.							
9	Mori, K. Ozeki, Y. Minami, A. Abe, H. Maeda, T. Akiyama, Y. Kanda, Y. Sato, S.							
10	Akinaga, T. Naoe, KW-2449, a novel multikinase inhibitor, suppresses the growth of							
11	leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation.							
12	Blood 114 (2009) 1607-1617.							
13	[47]D. Akahane, T. Tauchi, S. Okabe, K. Nunoda, K. Ohyashiki, Activity of a novel							
14	Aurora kinase inhibitor against the T315I mutant form of BCR-ABL: in vitro and in							
15	vivo studies. Cancer Sci. 99 (2008) 1251-1257.							
16	[48]M. Ninomiya, A. Abe, A. Katsumi, J. Xu, M. Ito, F. Arai, T. Suda, M. Ito, H. Kiyoi,							
17	T. Kinoshita, T. Naoe, Homing, proliferation and survival sites of human leukemia							
18	cells in vivo in immunodeficient mice. Leukemia 21 (2007) 136-142.							

1	[49]F. Ishikawa, S. Yoshida, Y. Saito, A. Hijikata, H. Kitamura, S. Tanaka, R. Nakamura							
2	T. Tanaka, H. Tomiyama, N. Saito, M. Fukata, T. Miyamoto, B. Lyons, K. Ohshima							
3	N. Uchida, S. Taniguchi, O. Ohara, K. Akashi, M. Harada, L.D. Shultz,							
4	Chemotherapy-resistant human AML stem cells home to and engraft within the							
5	bone-marrow endosteal region. Nat. Biotechnol. 25 (2007) 1315-1321.							
6	[50]V. Desplat, J.L. Faucher, F.X. Mahon, P. Dello Sbarba, V. Praloran, Z. Ivanovic							
7	Hypoxia modifies proliferation and differentiation of CD34(+) CML cells. Stem							
8	Cells 20 (2002) 347-354.							
9	[51]S. Giuntoli, E. Rovida, V. Barbetti, M.G. Cipolleschi, M. Olivotto, P. Dello Sbarba							
10	Hypoxia suppresses BCR/Abl and selects imatinib-insensitive progenitors with							
11	clonal CML populations. Leukemia 20 (2006) 1291-1293.							
12								
13								
1 /								

1 Figure legends.

Fig. 1. Growth inhibitory effect of AV65 in human CML cells. (A) Expression of $\mathbf{2}$ β-catenin in the K562, BV173, KT-1, and MYL CML cell lines and total BM cells from 3 4 a healthy volunteer (ctrl) as a control. (B) K562 cells were treated with AV65 and the expression of β -catenin was detected by Western blotting. Results represent the means $\mathbf{5}$ of 3 independent experiments. (C) Seven imatinib-sensitive human CML cell lines were 6 exposed to AV65 for 72 hours and anti-proliferative effects were examined using a 7 modified MTT assay. (D) The colony-forming assay was performed in duplicate in 8 primary CML cells obtained from patients with CML in the chronic phase and bone 9 marrow mononuclear cells obtained from healthy volunteers was performed in duplicate. 10 After 14 days of culture, colonies were evaluated under an inverted microscope. Data 11 12represents the mean \pm SD of 3 independent experiments.

13

14

Fig. 2. Effect of AV65 on the expression of β -catenin and its downstream targets. K562 CML cells were treated with AV65 at the indicated concentrations for 72 hours. Changes in the expression of β -catenin and its downstream effector proteins were evaluated.

2	Fig 3. Cell cycle analysis and transcript levels of CDK inhibitors in AV65-treated CML
3	cells. (A) K562 and BV173 were exposed to AV65 at a concentration of 10 nM for 12
4	hours. Apoptosis induced by AV65 was analyzed by PI and TUNEL double staining.
5	Each dot line in the scattergram indicates G1 phase. (B) CML cells treated with AV65
6	were fixed and stained with PI and analyzed for DNA content by FACS Canto II. The
7	numbers inside each histogram indicate the percentage of the subG1 fraction. The
8 9	results shown in Figure 2a and b are representative of 3 independent experiments. (C) Transcript levels of CKIs in CML cells detected by real time PCR analysis. The results
<i>3</i> 10	represent the means + SD of 3 independent experiments.
10	représent die means + 52 si é macpendent experiments.

11

Fig. 4. Induction of apoptosis by AV65 treatment in CML cells. (A) K562 and BV173 cells were exposed to AV65 for 24, 48, and 72 hours at concentrations of 10 nM and 30 nM. Cell were stained with PI and Annexin V-FITC and subjected to flow cytometric analysis for the determination of apoptosis. The numbers inside each histogram indicate the percentage of early apoptotic cells (Annexin-V+/PI-) and late apoptotic/necrotic cells (Annexin-V+/PI+). (B) K562 and BV173 were treated with AV65 in the presence of zVAD. Cell were stained with PI and Annexin V-FITC. The numbers inside each histogram indicate the percentage of early apoptotic cells (Region A) and late
apoptotic/necrotic cells (Region B). Results are representative of 3 independent
experiments.

4

Fig. 5. The inhibitory effects of AV65 in combination with IM on K562 cells. (A) K562 5 cells were incubated for 72 hours with 6 concentrations (0.25, 0.5, 0.75, 1.0, 1.5, or 2.0 6 times the IC_{50}) of AV65 and IM or a combination of the 2 agents using the constant ratio $\overline{7}$ design of a modified MTT assay. The IC_{50} values of AV65 and IM were 10 nM and 100 8 µM, respectively. The killing curves of the concurrent administration of AV65 and IM 9 are shown. (B) Plots of combination index (CI) against fraction affected (Fa). CIs were 10 11 determined with the nonlinear regression program CalcuSyn. 12Fig. 6. Inhibitory effect of AV65 on IM-resistant CML cells. (a) Four IM-resistant CML 13cell lines; K562/IMR (Bcr-Abl amplification), MYL-R1 (Lyn overexpressing), 14

15 KBM5/STI-R (harboring the T315I mutation), and K562/D1-9 (P-gp overexpressing),

16 were exposed to AV65 for 72 hours and its anti-proliferative effects were examined by a

- 17 modified MTT assay. The results represent the means \pm SD of 3 independent
- experiments. (B) KBM5 and KBM5/ STI-R cells were exposed to AV65 for 24, 48, and

1	72 hours at concentration of 1 x IC ₅₀ (20 nM, 15 nM, respectively) and 3 x IC ₅₀ (60 nM,
2	45 nM, respectively). Cell were stained with PI and Annexin V-FITC and subjected to
3	flow cytometric analysis of apoptosis. The numbers inside each histogram indicate the
4	percentage of early apoptotic cells (Annexin-V+/PI-) and late apoptotic/necrotic cells
5	(Annexin-V+/PI+). Results are representative of 3 independent experiments. (C) Total
6	protein lysates were extracted from the hypoxia-adapted CML cell lines, K562/HA and
7	KCL22/HA. Western blotting was performed using antibodies against β -catenin and
8	Actin (upper panel). Anti-proliferative effects were examined by the modified MTT
9	assay. Results represent the means \pm SD of 3 independent experiments (lower panel).

1 Figures

Fig. 1.






Fig. 2.

	AV	AV65 10 nM			65 30 n		
untreated	d 24	48	72	24	48	72	hrs
Phosphorylated β-catenin	and the other	Acres 1	and a	and a	-	-	
β-catenin	-	-	-	-	-	-	
β-actin	-	-	-	-	-	-	2
c-myc	-	-	unit.	-	-	-	8
β-actin 🛌	-	1	-	-	1	-	*
cyclin D1 🛌	-	-	_	-	1	_	
β-actin 💻	-	1	1	-	-	-	•
survivin	-	-	-	-	-	-	
β-actin 🛌	-	-	-	-	_	-	•




AV65 (nM)


1











 $\mathbf{2}$